Means Investment CO. Inc. Has $1.11 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Means Investment CO. Inc. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 68.1% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 16,016 shares of the company’s stock after selling 34,124 shares during the quarter. Means Investment CO. Inc.’s holdings in Novo Nordisk A/S were worth $1,112,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of NVO. Strategic Investment Solutions Inc. IL lifted its stake in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after buying an additional 300 shares during the last quarter. Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $29,000. Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $33,000. CX Institutional acquired a new position in shares of Novo Nordisk A/S in the first quarter valued at about $36,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $39,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of several research reports. Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, June 14th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an “underperform” rating on the stock. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Finally, Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Stock Down 0.4%

Shares of Novo Nordisk A/S stock opened at $74.03 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15. The firm’s 50-day moving average price is $68.23 and its two-hundred day moving average price is $78.93.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.